TuHURA Biosciences (NASDAQ:HURA – Get Free Report) and Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.
Insider & Institutional Ownership
0.6% of TuHURA Biosciences shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by insiders. Comparatively, 4.9% of Agios Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations for TuHURA Biosciences and Agios Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TuHURA Biosciences | 1 | 0 | 2 | 1 | 2.75 |
| Agios Pharmaceuticals | 1 | 4 | 6 | 0 | 2.45 |
Profitability
This table compares TuHURA Biosciences and Agios Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TuHURA Biosciences | N/A | -196.68% | -123.41% |
| Agios Pharmaceuticals | -895.86% | -28.35% | -26.42% |
Volatility and Risk
TuHURA Biosciences has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.
Earnings and Valuation
This table compares TuHURA Biosciences and Agios Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TuHURA Biosciences | N/A | N/A | -$21.68 million | ($0.50) | -1.32 |
| Agios Pharmaceuticals | $36.50 million | 46.06 | $673.72 million | ($7.00) | -4.12 |
Agios Pharmaceuticals has higher revenue and earnings than TuHURA Biosciences. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.
About TuHURA Biosciences
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
